Low dose and dose escalating therapy of interferon alfa-2a in the treatment of refractory and sight-threatening Behçet's uveitis
Onal, S.; Kazokoglu, H.; Koç, A.; Akman, M.; Bavbek, T.; Direskeneli, H.; Yavuz, S.
Clinical and Experimental Rheumatology 27(2 Suppl 53: S113-S114
2009
ISSN/ISBN: 0392-856X PMID: 19796551 Document Number: 635334
Document emailed within 1 workday
Related Documents
Armenta, D.; Espallargas, C.; Paz, A.; Rodríguez Martorel, J.; Ladines, R.; Alvarez, C.; Román, J.; Andrés, P. 1996: Complete cytogenetic remission of chronic myeloid leukemia with low-dose interferon alfa-2b and monthly high-dose busulfan Sangre 41(6): 465-467Termeer, C.C.; Simon, J.C.; Schöpf, E. 2001: Low-dose interferon alfa-2b for the treatment of Churg-Strauss syndrome with prominent skin involvement Archives of Dermatology 137(2): 136-138
Mukaiyama, T.; Ogawa, M.; Horikoshi, N.; Inoue, K.; Aiba, K.; Matsuoka, A.; Matsumura, T.; Ogihara, A.; Sumida, T. 1992: High-dose thio-TEPA with escalating doses of epirubicin and autologous hematopoietic stem cell transplant for refractory cancers Gan to Kagaku Ryoho. Cancer and ChemoTherapy 19(2): 189-194
Mulder, P.O.; Sleijfer, D.T.; Willemse, P.H.; de Vries, E.G.; Uges, D.R.; Mulder, N.H. 1989: High-dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors Cancer Research 49(16): 4654-4658
Zouboulis, C.C.; Orfanos, C.E. 1998: Treatment of Adamantiades-Behçet disease with systemic interferon alfa Archives of Dermatology 134(8): 1010-1016
Guilhot, F. 1993: Interferon alfa and low-dose cytosine-arabinoside for the treatment of patients with chronic myelogenous leukemia in chronic phase. French CML Study Group Seminars in Hematology 30(3 Suppl 3: 24-25
Davis, J.C.; Fessler, B.J.; Tassiulas, I.O.; McInnes, I.B.; Yarboro, C.H.; Pillemer, S.; Wilder, R.; Fleisher, T.A.; Klippel, J.H.; Boumpas, D.T. 1998: High dose versus low dose fludarabine in the treatment of patients with severe refractory rheumatoid arthritis Journal of Rheumatology 25(9): 1694-1704
Bernhard, H.; Klein, O.; Meyer zum Büschenfelde, K.H.; Knuth, A. 1992: Treatment of refractory colorectal carcinomas with fluorouracil, folinic acid, and interferon alfa-2a Seminars in Oncology 19(2 Suppl 3: 204-207
Fernández, I.; Castellano, G.; Canga, F.; Colina, F.; García, H.; Fuertes, A.; Casis, B.; Martín, A.; Solís, J.A. 1995: A comparative randomized controlled study of the efficacy of interferon alfa-2b and interferon alfa-2a in the treatment of chronic hepatitis C Gastroenterologia y Hepatologia 18(2): 66-72
Capizzi, R.L.; Powell, B.L. 1987: Sequential high-dose ara-C and asparaginase versus high-dose ara-C alone in the treatment of patients with relapsed and refractory acute leukemias Seminars in Oncology 14(2 Suppl 1: 40-50
Jonasch, E.; Kumar, U.N.; Linette, G.P.; Hodi, F.S.; Soiffer, R.J.; Ryan, B.F.; Sober, A.J.; Mihm, M.C.; Tsao, H.; Langley, R.G.; Cosimi, B.A.; Gadd, M.A.; Tanabe, K.K.; Souba, W.; Haynes, H.A.; Barnhill, R.; Osteen, R.; Haluska, F.G. 2000: Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma Cancer Journal 6(3): 139-145
Rakita, L.; Sobol, S.M. 1983: Amiodarone in the treatment of refractory ventricular arrhythmias. Importance and safety of initial high-dose therapy JAMA 250(10): 1293-1295
Demina, T.L.; Khachanova, N.V.; Davydovskaia, M.V. 2005: Use of beta-interferon in the treatment of multiple sclerosis: high-rate injectable dose therapy Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 105(5): 76-79
Colpaert, F.C.; Janssen, P.A. 1982: Factors regulating drug cue sensitivity: the effects of dose ratio and absolute dose level in the case of fentanyl dose-dose discrimination Archives Internationales de Pharmacodynamie et de Therapie 258(2): 283-299
Corbillet, V.; Celerier, P.; Lebon, P.; Litoux, P.; Dreno, B. 1995: Development of interferon antibodies during the treatment of skin diseases with low-dose recombinant interferon alpha-2a Annales de Medecine Interne 146(6): 399-403
Cantini, F.; Salvarani, C.; Niccoli, L.; Padula, A.; Arena, A.I.; Bellandi, F.; Macchioni, P.; Olivieri, I. 1999: Treatment of thrombophlebitis of Behçet's disease with low dose cyclosporin a Clinical and Experimental Rheumatology 17(3): 391-392
Jehn, U.; Heinemann, V.; Wilmanns, W. 1989: Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogenous leukemia (AML) Anticancer Research 9(1): 119-124
Kotake, S.; Ichiishi, A.; Kosaka, S.; Yoshikawa, K.; Minagawa, R.; Matsuda, H. 1992: Low dose cyclosporin treatment for ocular lesions of Behçet's disease Nippon Ganka Gakkai Zasshi 96(10): 1290-1294
Ohshima, A.; Yoshida, K.; Sato, T.; Miyazaki, S.; Yanagisawa, M.; Nakayama, Y.; Takahashi, T.; Mamiya, S.; Fukusima, Y.; Miura, A.B. 1987: Intermediate- and high-dose cytosine arabinoside therapy in acute refractory leukemia Gan to Kagaku Ryoho. Cancer and ChemoTherapy 14(1): 192-195
Al-Shakarshi, J.S.H.; Bent-Hansen, L.; Jensen, G.B. 2004: Life-threatening, recurrent arrhythmia in patients on high-dose methadone treatment: torsade de pointes Ugeskrift for Laeger 166(36): 3104-3105